MEDIAR THERAPEUTICS
Mediar is a preclinical stage biotechnology company developing therapeutics to halt, or even reverse, fibrosis.
MEDIAR THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2019-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.mediartx.com
Total Employee:
11+
Status:
Active
Total Funding:
0
Technology used in webpage:
Viewport Meta SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Euro Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS
Similar Organizations
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Advisors List
Current Employees Featured
Founder
Investors List
Agent Capital
Agent Capital investment in Seed Round - Mediar Therapeutics
ONO Pharmaceutical
ONO Pharmaceutical investment in Seed Round - Mediar Therapeutics
Pfizer Venture Investments
Pfizer Venture Investments investment in Seed Round - Mediar Therapeutics
Mission BioCapital
Mission BioCapital investment in Seed Round - Mediar Therapeutics
Mass General Brigham Ventures
Mass General Brigham Ventures investment in Seed Round - Mediar Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-15 | Simon Sturge Joins Mediar Therapeutics as Executive Chairman |
Official Site Inspections
http://www.mediartx.com
- Host name: 245.112.199.104.bc.googleusercontent.com
- IP address: 104.199.112.245
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Mediar Therapeutics"
Mediar Therapeutics
Mediar is pioneering a new approach to fibrosis treatment that aims to halt the disease at a different source – the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, …See details»
Mediar Therapeutics - Crunchbase Company Profile
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis. Its therapeutics target key fibrotic mediator proteins that aid in the development of fibrosis in chronically-damaged organs. The …See details»
Investors - Mediar Therapeutics
Fearlessly pioneering novel therapies to make meaningful impact and provide hope for patients with fibrotic diseases.See details»
Our Team - Mediar Therapeutics
Paul Yaworsky is the founding CSO of Mediar Therapeutics. He joined Mediar from Pfizer, where he spent more than 20 years focused on drug discovery and development. At Pfizer, Paul …See details»
Mediar Therapeutics Company Profile 2024: Valuation, …
Developer of innovative fibrosis treatment intended for halting and reversing fibrotic activity.See details»
Mediar Therapeutics - LinkedIn
Mediar Therapeutics is a biotechnology company pioneering a new approach to fibrosis treatment that halts the disease at a different source – the fibrotic mediators that drive disease...See details»
Mediar Therapeutics Initiates Second Clinical Program in Portfolio …
Mediar Therapeutics, Inc., a clinical stage biotechnology company advancing a portfolio of first-in-class therapies designed to halt fibrosis progression, today announced the first cohort of...See details»
Mediar Therapeutics announces clinical candidates for lead fibrosis ...
Oct 25, 2023 · Mediar’s first candidate, MTX-463, is a first-in-class monoclonal antibody designed to neutralize the WISP-1 signaling that is elevated in and contributes to fibrosis progression.See details»
Mediar Therapeutics - VentureRadar
Website: https://www.mediartx.com/ Develops innovative fibrosis treatments by targeting fibrotic mediators, focusing on late-stage conditions in lung and liver, with potential expansion to renal …See details»
Simon Sturge Joins Mediar Therapeutics as Executive …
Sep 15, 2021 · Mediar Therapeutics is a discovery stage biotechnology company developing treatments to halt, or even reverse, fibrosis. Our platform and pipeline are based on an emerging class of novel targets...See details»
Mediar Therapeutics Announces $105 Million Financing to
Mar 15, 2023 · Mediar was founded on pioneering fibrosis research from Mass General and Brigham and Women's Hospitals in partnership with Mass General Brigham Ventures with the …See details»
Our Values - Mediar Therapeutics
Our team is driven to serve patients and their families by discovering and developing innovative therapies for the treatments of fibrotic diseases. [Mediar CMO, Jeff Bornstein, MD speaks in …See details»
Mediar advances first-in-class fibrosis portfolio to the clinic with ...
May 6, 2024 · As Mediar advances MTX-463 and MTX-474 into human studies, it will be guided by its clinical advisory board, comprising world renowned leaders in fibrosis across …See details»
Mediar Therapeutics Initiates Second Clinical Program in
BOSTON, Aug. 7, 2024 /PRNewswire/ -- Mediar Therapeutics, Inc., a clinical stage biotechnology company advancing a portfolio of first-in-class therapies designed to halt fibrosis progression, …See details»
Mediar Therapeutics - Overview, News & Similar companies
Mediar Therapeutics contact info: Phone number: (617) 564-1370 Website: www.mediartx.com What does Mediar Therapeutics do? Mediar Therapeutics is a preclinical stage biotechnology …See details»
Microsoft Word - Mediar Series A Press Release 031523.docx
CAMBRIDGE, Mass., March 15, 2023 – Mediar Therapeutics Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt and even reverse the course of …See details»
Mediar gets a spark from Pfizer’s Ignite program - Fierce Biotech
Oct 25, 2023 · Mediar Therapeutics is tapping the business development well early, teaming up with Pfizer and WuXi Biologics as two assets near the clinic. The fibrosis-focused biotech will …See details»
Privacy Policy - Mediar Therapeutics
Mar 9, 2023 · Mediar Therapeutics is a preclinical stage biotechnology company developing therapeutics to halt, or even reverse, fibrosis. Our Site is intended to provide visitors with …See details»